cell therapy
-
Without Change, Lifesaving HCT and Cell Therapies Will Be Out of Reach for Many
Ending access and outcomes disparities in HCT and cell therapy will require a collaborative effort, from clinicians, associations and non-profit organizations in the hematology/oncology, HCT and cell therapy communities to policy makers and payers
-
J&J Expands in Cancer, Paying $245M for Two Next-Generation Cell Therapies
Johnson & Johnson is acquiring rights to two next-generation cell therapies from Cellular Biomedicines, both potential treatments for diffuse large B-cell lymphoma. One therapy is already in the clinic while the other is on track to begin human testing this year.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
How Gamida Cell’s FDA Approval Could Reduce Racial Disparities in Stem Cell Transplants
The FDA approved Omisirge, an allogeneic cell therapy from Gamida Cell that could improve access to stem cell transplants as treatments for blood cancers. The biotech makes its therapy from umbilical cord blood.
-
Sponsored Post, BioPharma, Payers
What Do Payers Need to Help Value-Based Contracting Deals for Novel Therapies Succeed?
A panel discussion at the annual Abarca Forward conference in Puerto Rico last month sought to identify some of the innovative financial approaches that can be applied to managing the high price of novel therapies. Conversations also addressed what payers need for these financing models to be sustainable.
-
Cell Therapy Pioneers Team Up to Found Viral Vector CDMO Backed by $64M
VintaBio manufactures AAV and lentiviral vectors for entities pursuing clinical development of cell and gene therapies. The contract development manufacturing organization’s launch comes as demand for viral vectors continues to outpace the supply of these crucial components of the therapies.
-
Regeneron Jumps Into Cell Therapy via Alliance With Treg Startup Sonoma Bio
Regeneron is paying Sonoma Biotherapeutics $75 million to begin a partnership focused on developing cell therapies based on regulatory T cells, or Tregs. Each company brings technological capabilities to the alliance, which is initially focused on ulcerative colitis and Crohn’s disease.
-
Adaptimmune, TCR2 Therapeutics to Combine in Marriage of Cell Therapy Developers
Adaptimmune and TCR2 Therapeutics have complementary technologies and an aligned strategy of developing cell therapies for solid tumors, but this marriage is preceded by divorce. Before consummating the TCR2 deal, Adaptimmune ended an alliance with a larger pharmaceutical company.
-
With New Kind of CAR, Cancer Startup Cargo Refuels With $200M for Cell Therapy Race
Cargo Therapeutics is developing CAR T-cell therapies that overcome ways cancers evade currently available treatments. True to its name, the startup’s approach involves putting more cargo and more complex cargo onto engineered T cells.
-
Cell Therapy Biotech Talaris Ends Two Kidney Transplant Trials, Restructures
While Talaris Therapeutics is ending two clinical tests of its cell therapy in kidney transplant patients, a third study in the autoimmune condition scleroderma is continuing. Meanwhile, the biotech’s restructuring plan is pursuing “strategic alternatives” that could include a merger or sale.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
MD Anderson’s Tech Puts Replay on Fast Path to Clinic With TCR NK Cell Therapies
Syena, the latest company formed by startup creator Replay, is developing cancer treatments based on a type of immune cell called a natural killer cell. This NK cell therapy technology, licensed from The University of Texas MD Anderson Cancer Center, could overcome many of the limitations facing first-generation cell therapy.
-
CDMO Startup Vector BioMed Launches to Fill Lentiviral Gap for Cell & Gene Therapies
Vector BioMed has developed a technology platform for designing and manufacturing the lentiviruses used to deliver cell and gene therapies. The startup is launching as the field continues to experience shortages of these viral vectors.
-
As Cell Therapy Gains Ground, Efforts Emerge to Improve CAR T-Manufacturing
Cell therapy offers a treatment option for some advanced blood cancers, but the manufacturing process is lengthy and complex. The biopharmaceutical industry is working on various technologies that could make manufacturing faster and more efficient, or perhaps supplant the current process altogether.
-
Atara Approval Marks Cell Therapy First; Entrada on Hold, Bluebird Freed & More
The first regulatory approval of an allogeneic cell therapy goes to Atara Biotherapeutics. Other regulatory news highlights from the past week include proposed reforms of the FDA’s accelerated approval process, approval of the first gene therapy for bladder cancer, and a clinical hold for a biotech developing a new class of medicines.
-
Gilead’s Kite Unit Strikes Another Cell Therapy Deal to Pursue Next-Gen CAR T
Kite, the cell therapy unit of Gilead Sciences, is adding more tools to its cell therapy toolbox with the acquisition of Tmunity Therapeutics. It’s the company’s second cell therapy deal this month, following a partnership announced with clinical-stage Arcellx.
-
2023 Likely To Be a Crucial Year for Pharma—and Insurers
2023 is shaping up to be a crucial year for everyone involved – and affected – by the pharmaceutical industry. It’s likely to be a year of experimentation for payers – and defensiveness for drug makers.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
